Opinion

Video

PARP Inhibitors in Metastatic Prostate Cancer: Efficacy, Trials, and Combination Therapies

Key Takeaways

  • Olaparib significantly improved radiographic progression-free survival and overall survival in metastatic prostate cancer with HRR gene alterations.
  • Safety profiles of PARP inhibitors were consistent with known effects, with manageable adverse events observed.
SHOW MORE

Panelists discuss how the PROfound trial (NCT02987543) demonstrated the efficacy and safety of olaparib monotherapy in metastatic prostate cancer patients with homologous recombination repair gene alterations, highlighting its potential as a targeted treatment option and its impact on the landscape of precision medicine in prostate cancer management.

Video Content above is prompted by the following:

  • Discuss efficacy and safety findings from monotherapy trials PARP inhibitors in metastatic prostate cancer harboring homologous recombination repair gene alterations.
    • PROfound trial (olaparib), NCT02987543
Related Videos
Michael Jenson, PA-C, answers a question during a Zoom video interview
Couple talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
Andrew C. Peterson, MD, MPH, answers a question during a Zoom interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Oliver Sartor, MD, is featured in this series.
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
Oliver Sartor, MD, is featured in this series.
1 KOL is featured in this series.
Michael Jenson, PA-C, answers a question during a Zoom video interview
© 2024 MJH Life Sciences

All rights reserved.